According to the pharmaceutical and biotech industry on the 17th, Celltrion Healthcare Japan, Celltrion’s Japanese subsidiary, announced on the 5th that it would lift the limited shipment restrictions on the 200 mg version of Aptozma—a biosimilar of Actemra (active ingredient: tocilizumab)—for medical institutions and pharmaceutical distributors in Japan. The restriction will be lifted starting with orders placed on the 24th. The announcement stated that the shipment restrictions on this specific dosage form—which had previously been subject to limited distribution—would be lifted.
It is reported that Celltrion’s Japanese subsidiary has been expanding supply volumes through adjustments to production plans and has determined that it has reached a level capable of meeting local demand. Consequently, the restrictions that had been applied when medical institutions and distributors placed new orders will be lifted.
Supply adjustments have been ongoing since the product’s launch. Celltrion launched Aptosma in Japan on April 28. It was the first to-cilizumab biosimilar to enter the Japanese market. At the time of launch, Celltrion stated that its Japanese subsidiary would sell the product directly and leverage the sales experience and local network built through the sale of existing autoimmune disease treatments to establish a foothold in the market.
However, on June 15—about a month and a half after launch—the Japanese subsidiary announced that it would limit shipments of the 200 mg product due to supply and demand conditions. It was reported that orders from medical institutions had increased faster than initially anticipated after launch, making it difficult to fully meet the demand for the 200 mg product with existing production plans alone. In effect, the supply volume prepared for the initial market entry could not keep pace with the actual rate of order growth.
At the time, the company requested that medical institutions already receiving Aptozma continue to be supplied as usual, while those considering new adoption should consult with sales representatives in advance. Given the limited supply of the 200 mg dosage, the company also recommended the 80 mg and 400 mg products—which contain the same active ingredient—as alternative dosages. In the pharmaceutical supply status report released by Japan’s Ministry of Health, Labor and Welfare, Celltrion’s Tocilizumab BS 200 mg was classified as having limited shipments, while the 80 mg and 400 mg dosages were listed as having normal shipments.
Celltrion has been working to establish Aptozma in the market by leveraging its existing product portfolio in Japan. The strategy involves connecting the relationships with healthcare professionals and medical institutions—built through the sales of existing autoimmune disease products such as Remsima and Uplima—to the sales of follow-up products. Providing product-related academic information and presenting clinical data to healthcare professionals at the Japanese Society of Rheumatology prior to Aptozma’s launch was also part of the preparation for market entry.
However, it appears that the faster-than-expected growth in demand during the initial launch phase led to supply adjustments. In essence, there was a gap between the initial sales pace and the existing production plan. It is reported that orders from medical institutions for Aptozma exceeded expectations from the very beginning of its launch in Japan, and it was difficult to fully meet the demand for the 200 mg dosage with the originally planned production volume alone. Consequently, while maintaining treatment continuity for existing patients and medical institutions within the available supply, the company directed medical institutions considering new adoption toward other dosage forms.
A Celltrion official stated, “In the case of Aptozma in Japan, we have been adjusting supply volumes as part of a strategy to maintain stable supply as market demand increased,” adding, “We subsequently adjusted our production and supply systems to reflect market demand, and as a result, we shifted our shipment strategy once supply volumes expanded to a level capable of meeting local demand.”
Meanwhile, with shipping restrictions set to be lifted for orders placed on or after the 24th, accessibility for local Japanese medical institutions that have been considering adopting the product is expected to improve further. Accordingly, Celltrion has indicated that it will continue to monitor demand in the Japanese market. A company spokesperson said, “We plan to continue monitoring demand in the Japanese market and strategically manage our business to ensure a stable supply of pharmaceuticals.”